ImmunityBio, Inc. SEC filings IBRX

ImmunityBio, Inc. has 554 filings in SEC EDGAR's recent list, going back to Apr 29, 2005. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 4, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

ImmunityBio, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
10-K Annual report Feb 23, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 30, 2025 Dec 31, 2024
10-K Annual report Mar 3, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 29, 2024 Dec 31, 2023
10-K Annual report Mar 19, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 1, 2023 Dec 31, 2022
10-K Annual report Mar 1, 2022 Dec 31, 2021
10-K Annual report Mar 4, 2021 Dec 31, 2020
10-K Annual report Mar 25, 2020 Dec 31, 2019
10-K Annual report Mar 13, 2019 Dec 31, 2018
10-K Annual report Mar 12, 2018 Dec 31, 2017
10-K Annual report Mar 15, 2017 Dec 31, 2016
10-K Annual report Mar 30, 2016 Dec 31, 2015

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IBRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
Large accelerated filer
SEC CIK
1326110
Former names
NantKwest, Inc. (until Mar 8, 2021); Conkwest, Inc. (until Jul 13, 2015); ZelleRx Corp (until Oct 9, 2009)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.